We determined the clinical add-on effect of tiotropium in patients with severe bronchial asthma without COPD. Twenty-one patients with severe persistent (step 4) bronchial asthma, suffering from persistent symptoms and treated with the highest-dose of inhaled corticosteroids, a long-acting β2- agonist, and a leukotriene receptor antagonist, excluding those who definitely had COPD, inhaled tiotropium 18μg once daily, and those determined at Week 4 of treatment were compared with those at pre-treatment. The morning PEF increased from 271.0±26.1 l/min pre-treatment to 305.2±26.6 l/min at Week 4, showing a statistically significant improvement (p=0.0086). Similarly, FEV1 exhibited a statistically significant improvement from 1450.0±132.9 ml during pre-treatment to 1526.7±131.9 ml at Week 4 (p=0.0067). Improvements in subjective symptoms were also noted in 18 of the 21 subjects. This study suggests that tiotropium has the potential to be re-classified as a controller drug for longterm asthma management.
|Number of pages||5|
|Journal||Japanese Journal of Chest Diseases|
|Publication status||Published - 2007|
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine